STXSHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Stereotaxis, Inc. hold a median 12-month price target of $3 — +214.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 3 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Stereotaxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +214.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 12 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 13 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 Dec 2025 | Citizens | Initiates | Market Outperform | — |
| 12 Nov 2025 | Roth Capital | Reiterates | Buy | — |
| 5 Nov 2025 | Roth Capital | Reinstates | Buy | $4.00 |
| 5 Mar 2024 | Lake Street | Maintains | Buy | — |
| 5 Mar 2024 | Roth MKM | Reiterates | Buy | — |
| 10 Jan 2024 | Roth MKM | Initiates | Buy | — |
| 6 Mar 2023 | B. Riley Securities | Maintains | Buy | — |
| 6 Mar 2023 | Lake Street | Maintains | Buy | — |
| 6 Mar 2023 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2022 | Cowen & Co. | Maintains | Outperform | — |
| 2 Sept 2022 | B. Riley Securities | Initiates | Buy | — |
| 12 July 2022 | Aegis Capital | Initiates | Buy | — |
| 23 June 2022 | B. Riley Securities | Initiates | Buy | — |
| 5 Jan 2022 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2022 | Loop Capital | Initiates | Buy | — |
| 26 May 2021 | Piper Sandler | Initiates | Overweight | — |
| 8 Sept 2020 | Northland Capital Markets | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STXS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Stereotaxis, Inc. returned −64.6% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 43% of US stocks
Cheaper than 14% of US stocks
Cheaper than 81% of US stocks
Higher than 14% of US stocks
Higher than 25% of US stocks
Higher than 72% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
Higher than 8% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stereotaxis, Inc. has a market value of $84.5M and an enterprise value of $88.1M.
Revenue in the twelve months to 30 June 2026: $30.1M. The latest quarter shrank 12.8% year on year.
Net income over the same four quarters: −$22.3M, a −74.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.24.
Free cash flow in the twelve months to 30 June 2026: −$15.5M.
Trailing P/E: −3.4×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Stereotaxis, Inc. employs 131 people — $230K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stereotaxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Stereotaxis announced that first-in-human results for Robocath’s next-generation robotic system were presented at the TCT conference. The study reported a 100% clinical success rate and no device-related complications.
Why it matters — The results highlight clinical performance of a robotic system referenced in an announcement from Stereotaxis.
Stereotaxis announced that Pauls Stradiņš Clinical University Hospital in Riga established Latvia’s first robotic center for cardiac arrhythmia treatment and treated its initial patients using the Genesis Robotic Magnetic Navigation System.
Why it matters — The announcement marks the first reported use of Stereotaxis’s Genesis system at a cardiac arrhythmia center in Latvia.
Stereotaxis announced that it will report its 2026 third-quarter financial results after U.S. markets close on November 10, 2026. It will host a conference call and webcast at 4:30 p.m. EST to discuss the results and corporate developments.
Why it matters — STXS watchers can note the scheduled date and time for the company’s quarterly results and accompanying discussion.
Stereotaxis announced that its emerging digital, AI and automation capabilities, including Synchrony and SynX, will be featured at the Heart Rhythm Society's HRX 2026 conference. Additionally, the Stereotaxis CEO will join a main-stage panel on Autonomous EP Systems.
Why it matters — STXS watchers would care because showcasing its new digital and autonomous technologies at a major industry conference highlights the company's strategic focus on advancing its product pipeline and gaining visibility in the electrophysiology space.
Stereotaxis announced that the Electrophysiology team at the University of Szeged in Hungary treated over 70 patients using the Genesis Robotic Magnetic Navigation system just over a month after launching its robotic cardiology program, marking the program's strongest first month.
Why it matters — A strong early patient volume at a new European site indicates growing real-world adoption of Stereotaxis' Genesis system in clinical practice.
The 3 Wall Street analysts covering Stereotaxis, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Stereotaxis, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stereotaxis, Inc. 32 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Stereotaxis, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +214.2% from the last close, and Ticker Nerd's factor model ranks Stereotaxis, Inc. 32 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stereotaxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
Stereotaxis, Inc. returned -64.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Stereotaxis Inc. is a medical technology company that develops robotic systems, instruments, and information solutions for interventional medicine.
The most recent item we track (GlobeNewsWire, 2 Nov 2026): "First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT". Stereotaxis announced that first-in-human results for Robocath’s next-generation robotic system were presented at the TCT conference. The study reported a 100% clinical success rate and no device-related complications.
Stereotaxis Inc. is a medical technology company that develops robotic systems, instruments, and information solutions for interventional medicine. The company’s core offerings include robotic magnetic navigation platforms, such as Genesis RMN and GenesisX, which are designed to help physicians perform complex catheter-based procedures with computer-guided precision. Stereotaxis also provides the Odyssey Solution for procedure management and integrated information sharing, along with related imaging systems, disposables, and accessories used in cardiac and endovascular workflows. Its products are used primarily in electrophysiology and other minimally invasive interventions, supporting treatment of heart rhythm disorders and other vascular conditions. Based in St. Louis, Missouri, Stereotaxis focuses on combining robotics, imaging, and lab connectivity to improve clinical control and procedural efficiency in modern hospital interventional suites.
CEO Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. · 131 employees · United States · https://www.stereotaxis.com
